Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Summary
HR8205 reauthorizes ALS research programs through FY2031 but authorizes zero appropriated dollars. The bill is early-stage (referred to committee, no floor vote). Pure-play ALS firms like Cytokinetics are structurally most exposed, but the lack of appropriation and early legislative stage mean no near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8205 authorizes zero dollars — this is a procedural extension, not a spending bill
- 2.The bill is early-stage — referred to committee with no floor schedule
- 3.Pure-play ALS biotech $CYTK shows no price reaction to the bill's introduction
- 4.No companion Senate bill exists, reducing near-term passage probability
Market Implications
This bill has no near-term market implications. is the most exposed ticker structurally, but the company's current stock price ($63.84) and recent 30-day decline of 3.14% reflect pipeline risks and broader biotech sentiment, not ALS legislation. Investors should watch for (a) committee markup, (b) a companion Senate bill, and (c) any appropriations language attaching dollars to the reauthorization — none of which exist today.
Full Analysis
-
What happened: Representative Quigley (D-IL) introduced HR8205 on April 6, 2026, referred to the House Energy and Commerce Committee. The bill would extend the Accelerating Access to Critical Therapies for ALS Act (Public Law 117-79) through FY2031, adding new FDA oversight provisions for requesting interim clinical trial data and clarifying that phase 2/3 combined trials count as phase 3 for program eligibility. It also includes a non-binding Sense of Congress supporting direct appropriation for ALS programs.
-
The money trail: This is a pure authorization bill with zero appropriated funds. The bill merely extends the sunset of existing programs from 2026 to 2031 and adds procedural tweaks. The Sense of Congress section explicitly acknowledges that funding requires separate appropriations. No dollar amounts appear anywhere in the bill text. For retail investors, this means the bill has no immediate ability to fund research grants, contracts, or drug purchases.
-
Structural winners and losers: The only pure-play ALS biotech exposure is Cytokinetics, which has ALS-related programs but whose primary pipeline is in cardiac muscle biology. Other companies with ALS exposure include Biogen ($BIIB, FDA-approved Qalsody for SOD1-ALS) and AbbVie ($ABBV, no ALS therapy). The structural linkage to is weak—ALS is not the company's primary revenue driver, and the bill provides no funding.
-
Real market data analysis: is at $63.84, down 2.27% over 7 days and 3.14% over 30 days. The introduction of HR8205 on April 6 shows no discernible price effect ( closed at $66.71 on April 17, well after introduction, and has since declined). $BIIB at $191.46 shows a 4.43% 30-day gain driven by broader factors, not ALS legislation. $ABBV at $213.01 has a 7.2% weekly gain unrelated to this bill.
-
Timeline: This bill has no committee markup scheduled, no companion Senate bill (no related bills listed), and 35 cosponsors (all House). For context, similar ALS reauthorization bills in past congresses have taken 6–18 months to pass. The 119th Congress has 1.5 years remaining. Passage probability is moderate but distant.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Accelerating Access to Critical Therapies for ALS Act
Justice for ALS Veterans Act of 2025
ALS Disability Insurance Access Act of 2019
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →